Épisode 57 | COVID-19 : Thérapies alternatives

Après avoir parlé du Paxlovid, on s’intéresse aux thérapies alternatives contre la COVID. Quelles sont les données d’efficacité concernant le remdésivir, la fluvoxamine et le budésonide inhalé? Quelles clientèles peuvent bénéficier de ces traitements? On en discute avec Jean-François Tessier, pharmacien à l’hôpital Maisonneuve-Rosemont du CIUSSS de l’Est-de-l’Ile de Montréal et président du RPE d’infectiologie de l’A.P.E.S.

RÉFÉRENCES : 
Anil Gupta A, Gonzalez-Rojas Y, Juarez E et al.  Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med 2021; 385:1941-1950. DOI: 10.1056/NEJMoa2107934.

Hammond J, Leister-Tebbe H, Gardner A et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022 (February). DOI: 10.1056/NEJMoa2118542.

Lee T C, Morris M, Grover A S et al. Outpatient therapies for COVID-19: How do we choose? medRxiv 2021.12.17.21268007. DOI: 10.1101/2021.12.17.21268007

Canadian Treatments for COVID-19 for the Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network and the Canadian Critical Care Trials Group. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ February 22, 2022 194 (7) E242-E251; DOI: 10.1503/cmaj.211698

Sanjay Ramakrishnan S, Nicolau Jr D V, Langford B et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine, volume 9, issue 7, p763-772, july 01, 2021. DOI: 10.1016/S2213-2600(21)00160-0

Robert L. Gottlieb, R, Vaca C E, Paredes R et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med 2022; 386:305-315. DOI: 10.1056/NEJMoa2116846.

COVID-19 advisory for Ontario. Science table. https://covid19-sciencetable.ca